title: Follow-up of recurrent hepatitis B and delta infection in liver allograft recipients after treatment with recombinant interferon-alpha.
abstract: Reinfection of the graft with hepatitis B virus (HBV) and hepatitis delta virus (HDV) is a potential complication in patients undergoing orthotopic liver transplantation (OLT). Therefore, we added recombinant interferon-alpha (rIFNa) to the standard immunosuppressive regimen in 11 patients who received transplants following liver failure attributed to cirrhosis B (n = 10, with HDV co-infection in four cases) or fulminant hepatitis B (n = 1). Patients were treated with rIFNa for periods ranging from 2 to 3 months between the first and the 13th month after OLT. All patients received immunosuppressive treatment with low-dose corticosteroids, azathioprine and cyclosporine. Anti-HBs hyperimmune globulin was also administered. None of the patients showed evidence of severe allograft rejection. Seven patients suffered HBV reinfection of the graft with histological signs of acute hepatitis in five cases and transition to chronic hepatitis in one patient. Treatment with rIFNa did not prevent or reduce HBV replication. Reinfection of the graft with HDV was demonstrated by PCR in four patients co-infected with HDV. During treatment with rIFNa liver biopsy specimens from three reinfected patients were transiently negative for HDV antigen but not for HDV RNA, and the sera from two patients were transiently negative for HDV RNA. The data indicate that rIFNa can reduce HDV replication in reinfected liver allografts.
authors.affiliation: Medizinische Klinik, Universitätsklinikum Rudolf Virchow, Standort Charlottenburg, Freie Universität Berlin, Federal Republic of Germany.
authors.forename: U
authors.initials: U
authors.lastname: Hopf
authors.forename: P
authors.initials: P
authors.lastname: Neuhaus
authors.forename: H
authors.initials: H
authors.lastname: Lobeck
authors.forename: V
authors.initials: V
authors.lastname: König
authors.forename: S
authors.initials: S
authors.lastname: Küther
authors.forename: J
authors.initials: J
authors.lastname: Bauditz
authors.forename: W O
authors.initials: WO
authors.lastname: Bechstein
authors.forename: G
authors.initials: G
authors.lastname: Blumhardt
authors.forename: R
authors.initials: R
authors.lastname: Steffen
authors.forename: R
authors.initials: R
authors.lastname: Neuhaus
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006509:Hepatitis B / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control; D006515:Hepatitis B virus / Q000502:physiology; D003699:Hepatitis D / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control; D003698:Hepatitis Delta Virus / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007370:Interferon Type I / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000601:surgery; D016031:Liver Transplantation / Q000009:adverse effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins; D012008:Recurrence; D014184:Transplantation, Homologous; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000305:Adrenal Cortex Hormones; D007370:Interferon Type I; D011994:Recombinant Proteins; D016572:Cyclosporine; D001379:Azathioprine